Nutrition Therapy Cost Analysis in the US by Robin S. Turpin et al.
Nutrition Therapy Cost Analysis in the US
Pre-Mixed Multi-Chamber Bag vs Compounded Parenteral
Nutrition
Robin S. Turpin,1,2 Todd Canada,3 Frank Xiaoqing Liu,1 Catherine J. Mercaldi,4
Alessandro Pontes-Arruda5 and Paul Wischmeyer6
1 Global Health Economics, Baxter Healthcare Corporation, Deerfield, IL, USA
2 Public Policy Department, Thomas Jefferson Hospital, Philadelphia, PA, USA
3 University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 United Biosource Corporation, Lexington, MA, USA
5 Intensive Care and Nutrition Department, Fernandes Ta´vora Hospital, Fortaleza, Ceara, Brazil
6 Department of Anesthesiology, University of Colorado, Denver, CO, USA
Abstract Background: Bloodstream infections (BSI) occur in up to 350 000 inpatient
admissions each year in the US, with BSI rates among patients receiving
parenteral nutrition (PN) varying from 1.3% to 39%. BSI-attributable costs
were estimated to approximate $US12 000 per episode in 2000. While pre-
vious studies have compared the cost of different PN preparation methods,
this analysis evaluates both the direct costs of PN and the treatment costs for
BSI associated with different PN delivery methods to determine whether
compounded or manufactured pre-mixed PN has lower overall costs.
Objective: The purpose of this study was to compare costs in the US asso-
ciated with compounded PN versus pre-mixedmulti-chamber bag (MCB) PN
based on underlying infection risk.
Methods:Using claims information from the Premier Perspective database,
multivariate logistic regression was used to estimate the risk of infection. A
total of 44 358 hospitalized patients aged ‡18 years who received PN between
1 January 2005 and 31 December 2007 were included in the analyses. A total
of 3256 patients receivedMCB PN and 41 102 received compounded PN. The
PN-associated costs and length of stay were analysed using multivariate or-
dinary least squares regression models constructed to measure the impact of
infectious events on total hospital costs after controlling for baseline and
clinical patient characteristics.
Results: There were 7.3 additional hospital days attributable to BSI. After
adjustment for baseline variables, the probability of developing a BSI was
30% higher in patients receiving compounded PN than in those receiving
MCB PN (16.1% vs 11.3%; odds ratio= 1.56; 95% CI 1.37, 1.79; p < 0.0001),
demonstrating 2172 potentially avoidable infections. The observed daily mean
PN acquisition cost for patients receiving MCB PN was $US164 (including
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all additives and fees) compared with $US239 for patients receiving com-
pounded PN (all differences p< 0.001). With a mean cost attributable to BSI
of $US16 141, the total per-patient savings (including avoided BSI and PN
costs) was $US1545.
Conclusion: In this analysis of real-world PN use, MCB PN is associated with
lower costs than compounded PN with regards to both PN acquisition and
potential avoidance of BSI. Our base case indicates that $US1545 per PN
patient may be saved; even if as few as 50% of PN patients are candidates for
standardized pre-mix formulations, a potential savings of $US773 per patient
may be realized.
Key points for decision makers
 Parenteral nutrition (supplied through an intravenous catheter directly into a vein in the arm or
chest) is used when oral or tube feeding is not possible in hospitalized patients who are at risk
of malnutrition, but increases the risk of bloodstream infection
 Bloodstream infection associated with parenteral nutrition added 7.3 days and $US16141 to
the average US hospital stay
 Bloodstream infection rates were 30% higher with parenteral nutrition compounded manually
or through a compounding device than with parenteral nutrition manufactured in a pre-mix
formulation
 The use of pre-mix rather than compounded parenteral nutrition offers potential savings of up
to $US1545 per patient, or between $US48million and $US96million in annual savings to the
US healthcare system
Background
The prevalence of hospital malnutrition has
been reported to range from 23% to 60% of all
hospital admissions.[1-6] While some of these in-
dividuals are malnourished upon admission, many
become depleted during hospital stay.[7] Surgery,
trauma, critical illness and infection are just some
of the conditions associated with increased nu-
trient requirements and the risk for developing
in-hospital malnutrition.[8]
Bloodstream infection (BSI) occurs in up to
350000 inpatient admissions each year in the US,[9]
and is considered one of the four major infection
types that together account for 78% of all hospital-
associated infections.[10] Moreover, with an at-
tributable mortality of 15%, BSI represents one
of the eight leading causes of in-hospital death in
the US,[9] depending on population character-
istics and illness severity. In addition to the human
toll consequential to infection, BSI-attributable
costs approximated $US12 000 per episode in
2000.[11]
The adverse impact of malnutrition can be
minimized with early supplemental feeding.[12]
Parenteral nutrition (PN) is used when enteral
nutrition (EN) fails or is contraindicated. Yet
PN is not without additional cost or risk of ad-
verse events, and BSI rates among PN patients
have been reported to vary widely (from 1.3% to
39%[13,14] depending on the patient population).
In the US, hospitals compound sterile in-
travenous admixtures, including PN, under the
guidance of the US Pharmacopeia Chapter 797
(USP).[15] Comprehensive and costly procedures
for controlling the environment, training pharmacy
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staff, handling the infusate and validating the
process are included in the published USP stan-
dards as a means to minimize contamination.[16]
Despite these recommendations, intravenous com-
pounding practices range from the poorly control-
led addition of drugs to an intravenous bag at the
bedside, to fully controlled compounding centres.[17]
Contamination rates during PN compounding
are estimated to range from 4.4% to 6.7%.[18,19]
Pre-mixed and ready-to-use products, for which
sterility is guaranteed by the manufacturing pro-
cess, require fewer additives and thereby mini-
mize the potential for touch contamination
during PN preparation and administration.[20-22]
According to publications by the USP[15] and the
American Society of Health System Pharma-
cists,[23] compounded formulations are generally
considered medium risk for patient exposure to
microbial and physical contaminants, while man-
ufactured pre-mix is considered low risk, pro-
vided any additions to the bag are sterile. In fact,
the US Joint Commission[24] recommends the use
of pre-mixed products whenever possible.
The decision around PN choice can be com-
plex, and there are no specific guidelines advising
the appropriate circumstances under which pre-
mixed, standardized or custom PN should be
used for various patient populations.[25,26] The
greatest potential disadvantage to pre-mixed
standardized PN appears to be the limited range
of formulae available, particularly in some coun-
tries. In addition, some populations, including
critically ill or fluid-restricted patients, or those
with organ dysfunction, may be more appro-
priately served with custom PN.[20]
Several studies have compared the cost of dif-
ferent PN compounding methods,[27-29] but there
have been no investigations of costs associated with
differential infection rates for various methods of
PN preparation. The purpose of this study was to
compare per-patient costs associated with com-
pounded PN versus pre-mixed multi-chamber
bag (MCB) PN based on underlying infection
risk. Since the method of PN preparation has
been demonstrated to have a significant impact
on infection rates,[30] it is expected that costs will
be lower for patients receiving PN delivered via
MCB than via compounded PN. However, the
extent of potential savings due to both the re-




We evaluated PN costs using claims data from
a nationally representative group of US hospitals
managed by Premier Healthcare Alliance, which
covers more than 400 hospitals in the US. The
Premier Perspective database includes patients’
complete billing and coding history at the level of
the individual patient. While typical claims data-
bases rely on charges only reimbursable by in-
surance for their economic analysis, Premier
Perspective has the advantage of having avail-
able the transaction-level cost data for each ad-
mission, including procedures and diagnostic,
therapeutic, laboratory and pharmacy services
(including PN and additives). The only costs not
included are physician or other provider charges
that are typically billed separately, either to a
payer or directly to the patient. All cost data were
inflation-adjusted to $US, year 2009 values.
Study Population
All hospital inpatients aged ‡18 years who re-
ceived any PN formulation between 1 January
2005 and 31 December 2007 were included. Any
patient who was admitted with infection, hepat-
ic dysfunction, acute cholecystitis, phlebitis or
thrombophlebitis was excluded from the anal-
yses. In addition, we excluded all patients with
renal failure or cirrhosis, since the costs asso-
ciated with their primary condition would skew
our economic analysis.1 Analysis of patients with
1 International Classification of Diseases, 9th edition (ICD-9) codes for exclusions are as follows: hypoglycaemia
251.2; hyperglycaemia 249, 790.29; hepatic dysfunction 570, 572.2; acute cholecystitis 575; phlebitis, thrombo-
phlebitis or pulmonary embolism 451.82, 451.83, 451.84, 415.1x; cirrhosis or chronic liver disease 571.x–573.x;
renal failure 584.x, 585.x.
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the above conditions, both with and without
renal failure or cirrhosis, will be reported else-
where.[30,31] The initial database contained over
11million inpatients, of which 73 048 patients re-
ceived at least one charge for PN. After excluding
all patients aged <18 years, and those admitted
with any of the previously mentioned diagnoses,
a total of 44 358 patients from 194 hospitals were
included in the final analyses.
Patients were classified as receiving PN via either
pre-mixed MCB (manufactured PN in a dual-
chamber bag with dextrose and amino acids,
which may have included additions of minerals,
vitamins, electrolytes or lipids; n = 3256) or com-
pounded admixture (either hospital compounded
or outsourced; n = 41 102).
Outcomes
The primary objective of this study was to
calculate the cost associated with different meth-
ods of delivering PN to patients. Economic out-
comes included hospital length of stay (LOS), use
of ICU and ICU LOS, and total hospital costs.
BSI, assumed to be a primary cost driver in this
analysis, was defined as any ICD-9 codes of 038.x
(septicaemia), 995.91 (sepsis), 995.92 (severe sepsis)
and 790.7 (bacteraemia). Outcomes were compared




Baseline demographics, co-morbidities and
hospitalization characteristics were reported de-
scriptively for each treatment group using means
(with SDs) and medians (with ranges) for con-
tinuous variables, and by raw counts (with per-
centages) for categorical measures. Differences
were reported using chi-squares for categorical
measures and t-tests for continuous variables.
Incidence rates for BSI were reported by treat-
ment group.
All Patient Refined DRG (APR-DRG) clas-
sifications are generally used to estimate severity
of illness and risk of mortality. Since all variables
used to calculate APR-DRG were available to
us, we included them individually in model esti-
mates. We did report proportions of APR-DRG
severity in the PN population for descriptive
purposes.
Risk of Bloodstream Infection (BSI)
Multivariate logistic regression was used to
create a model to estimate the risk of BSI for
patients receiving MCB versus compounded PN.
The model adjusted for baseline differences, risk
factors and potential confounders available in the
database, including hospital variables (size, geo-
graphical region, teaching status and urban/rural
location); patient demographics (age, sex, ethnicity,
payer); patient co-morbidities; and other indica-
tors of acuity defined by ICD-9 codes (nutritional
deficiency, intestinal malabsorption, acute pan-
creatitis, peritonitis, gastrointestinal fistula, Crohn’s
disease, cancer, diabetes mellitus, tuberculosis,
emergency or urgent admission, surgical status,
prior surgery or prior PN); and length of PN
treatment. Details on model development and
validation will be published in Mercaldi et al.[31]
The initial model contained all independent
variables listed above. Variable-selection proce-
dures were aimed at identifying a reduced set of
independent variables that provided the best fit
for the model. The final model was determined
using backward elimination variable selection,
with a significance level of 0.10 of the Wald chi-
squared statistic to specify the co-variates that
would remain in each step.Model fit was assessed
using the C-statistic, which corresponds to the
area under a receiver operating characteristic (ROC)
curve. The ROC curve indicates the probability
that randomly selected patients with the event
have a higher predicted probability of the event
than randomly selected patients without the
event. Risk of BSI was reported as adjusted prob-
ability of the event, and an odds ratio (OR) with
95% confidence levels. Further details on data in-
tegrity safeguards, the calculation of infection risk
and sensitivity analyses, including propensity score
modelling, will be published elsewhere.[30]
Length of Stay (LOS), BSI-Attributable Total and Daily
Parenteral Nutrition Costs
Baseline patient characteristics, including mark-
ers of severity, could affect our estimation of
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cost benefits. PN-associated costs and LOS were
estimated using multivariate ordinary least squares
regression models constructed to measure the
impact of infection events on total hospital costs
after controlling for baseline and clinical patient
characteristics. As both cost and hospital stay
data generally do not follow a Normal distribu-
tion and are often right-skewed, these variables
were transformed to their natural logs. Adjusted
mean log-costs and log-LOS were then retrans-
formed using Duan’s smearing estimate.[32] Sta-
tistical comparisons across groups were conducted
using t-tests of adjusted least squares mean log-
cost and log-LOS. The incremental difference in
adjusted mean hospital costs and LOS between
patients with and without an infection event was
assumed to be the total hospital costs and LOS
attributable to having an infection. This analysis
yielded estimates for costs and LOS that were
attributable to BSI. A similar analysis yielded an
adjusted difference in daily PN costs between the
two groups, controlling for baseline and clinical
patient characteristics.[31] PN costs for both
MCB and compounded PN included nutrient
additives and pharmacy labour as per the Premier
Perspective database. Since PN costs were
evaluated separately from BSI-attributable costs,
contributions of each to total savings could be
identified.
Avoidable BSI
If either method of PN preparation was asso-
ciated with fewer BSIs than the other method, the
number of potentially avoidable infections could
be calculated from ORs. However, if the OR
calculation was the product of logistic regression
and BSI incidence rates were greater than 10%,
both risk and avoidable infections (as calculated
from risk), could be overestimated.[33] To avoid
this, we performed a correction to our adjusted
ORs to more accurately represent relative risk.[33]
To estimate potentially avoidable BSIs for the
group with the higher rate of events, we calcu-
lated the difference between the number of ob-
served and expected events (equation 1):
Avoidable BSIs¼ number of actual events
 number of expected events ðEq: 1Þ
where the number of expected events was calcu-
lated by multiplying actual events by relative risk.
Calculation of Total Per-Patient Savings
While there were significant differences in
overall costs for the two groups, the intent of our
analysis was to identify the primary cost drivers.
Consequently, primary savings originated from
differences in daily PN cost, plus savings due to
avoidable BSIs. To calculate savings per patient
due to differences in PN cost, we multiplied the
difference in daily PN cost by the mean number
of PN days for the total population (equation 2):
Per-patient PN savings¼ difference in daily PN cost
mean days PN ðEq: 2Þ
where the difference in daily PN cost is the observed
difference adjusted for baseline characteristics.
To calculate per-patient savings due to avoid-
able BSI, avoidable BSI was multiplied by the
attributable costs for BSI, and divided by the
number of patients with the opportunity to avoid
BSI (equation 3):
Per-patient avoidable BSI Savings
¼ ðavoidable BSI  BSI-attributable costsÞ
n of patients in higher BSI rate group
ðEq: 3Þ
where the n of patients in the higher BSI rate group
represents the number of patients with the op-
portunity to avoid BSI.
To calculate the total per-patient cost savings,
we added per-patient PN savings to avoidable
BSI savings.
Sensitivity Analyses
In the first sensitivity analyses, logistic regres-
sion was repeated using both ICD-9 codes and the
administration of any intravenous antibiotic fol-
lowing the initiation of PN to identify BSIs. This
served as an accuracy check of the ICD-9 codes
used to identify BSIs. Second, minimum and maxi-
mum per-patient savings were calculated via a
series of one-way sensitivity analyses using 95%
confidence intervals for daily PN and avoidable
BSI. All three upper and all three lower limits
were then added to achieve an extreme sensitivity
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(absolute minimum and maximum) for total po-
tential per-patient savings.
As previously discussed, not all patients are
appropriate candidates for standardized pre-mix
PN formulae. The calculations in equations 1 and
2 assume that 100% of patients would be equally
appropriate for PN prepared by either method,
but this is not likely to be the case. Additional
sensitivities on total per-patient savings were cal-
culated, assuming 50%, 65%, 80% and 95% levels
of appropriateness for pre-mixed MCB PN.
Results
Baseline and Clinical Characteristics
Tables I and II compare the descriptive hos-
pital, patient and treatment variables for the two
groups. MCB PN was commonly used in urban
hospitals (62.4%), non-teaching hospitals (81.9%),
and those with fewer than 500 beds (96.7%), while
compounded PN was also commonly used in
urban hospitals (92.5%) and non-teaching hospitals
(54.0%), but in larger hospitals with 250–999
beds (88.8%). The proportion of hospitals using
MCB or compounded PN were significantly
(p < 0.01) different with regard to all hospital
characteristics, with the exception of hospital size
‡1000 beds (table I).
Patients who received PN via MCB were
slightly older (aged 66.2 vs 62.7 years), more
likely to have had an urgent or emergency ad-
mission (85.2% vs 74.2%), and more likely to be
on Medicaid or Medicare (70.5% vs 60.9%), yet
less likely to have an ICU stay (34.0% vs 45.0%)
than those receiving compounded PN; all differ-
ences p< 0.01 (table II). Patients in both groups
were equally likely to die in hospital (15.2% vs
18%). Patients receiving compounded PN were
more likely to have an APR-DRG severity rating
of ‘major’ or ‘severe’ (73.1% vs 65.1%), and to be
admitted with nutritional deficiencies (30.5% vs
26.8%), peritonitis (8.3% vs 5.4%), cancer (40.8%
vs 34.8%) or Crohn’s disease (3.2% vs 1.6%), and
were less likely to have diabetes mellitus (19.2%
vs 22.9%) than those receiving MCB PN; all dif-
ferences p < 0.01. With regards to PN treatment
(table II), patients in the compounded PN group
received PN for longer than those in the MCB
group (7.8 vs 5.2 days; p < 0.01).
BSI Rates, LOS and Costs
Figure 1 depicts the observed and adjusted BSI
rates for the two groups. There were 6788 BSIs
observed in the compounded PN group and 363
in the MCB PN group. The compounded PN
group demonstrated a 33% increase in observed
BSI rates over the MCB PN group (16.5% vs
11.1%; OR = 1.72; 95% CI 1.59, 1.85; p< 0.0001),
while the adjusted rates are associated with a 30%
higher probability of BSI in the compounded PN
group (16.1% vs 11.3%; OR = 1.56; 95% CI 1.37,
1.79; p< 0.0001). Further details on infection
rates and sensitivity modelling will be published
in Turpin et al.[30]
The observed differences in total LOS were
13.5 days for the MCB PN group and 16.9 days
for the compounded PN group. The additional
hospital days attributable to BSI were 7.3 days.
The MCB PN group had an observed daily mean
PN cost of $US164 (including all additives) for a
mean total PN cost of $US845; the compounded




















Location (% urban) 62.4 92.5*
a While patients only received either compounded or MCB PN,
there were nine hospitals that had both compounded and MCB
PN available.
MCB = pre-mixed multi-chamber bag; PN =parenteral nutrition;
*p < 0.01 vs MCB.
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PN group had a mean daily PN cost of $US239
(including all additives), with a mean total PN
cost of $US1681 (all differences p < 0.001). The
adjusted difference between groups (accounting
for baseline characteristics and clinical variables)
in PN daily cost was $US91.
Potentially Avoidable BSI
To estimate relative risk, a corrected OR was
calculated, as recommended by Zhang and
Yu.[33] Relative risk estimates indicate that 2172
of the 6788 BSIs experienced by the compounded
PN group may have been avoided by using MCB
PN (if 100%were appropriate for pre-mixedMCB
PN) [equation 4]:2
Avoidable BSI ¼ 6788 ð6788 0:68Þ ¼ 2172
(Eq: 4Þ
where 6788 is the number of compounded PN
patients, and 0.68 is the adjusted OR for BSI.
In a sensitivity analysis, the number of poten-
tially avoidable BSI is reduced by changing the
number of patients who were potential candi-
dates forMCB PN from 2172 (100% appropriate)
to 2063 (95% appropriate), 1738 (80% appropriate),
1412 (65% appropriate) and 1086 (50% appropriate).
Per-Patient Savings and Sensitivity Analysis
After adjusting for baseline characteristics, the
total per-patient PN cost for the MCB PN group
was $US91 less per day than for the compounded
PN group. To extrapolate the analysis to the en-
tire US population receiving PN, the mean
number of PN days for all patients in this analysis
was used (7.6 days). Per-patient PN savings were
estimated by multiplying the difference in daily






Age [y; mean (SD)] 66.2 (17.8) 62.7 (17.7)*
Gender (% male) 41.0 43.5*
Major or extreme APR-DRG severity (%) 65.1 73.1*
Urgent or emergency admission (%) 85.2 74.2*
Payer (% public)a 70.5 60.9*
Surgical treatment (%) 71.7 85.2*
Inpatient mortality (%) 15.2 18
Total duration of hospital stay [d; mean (SD)] 13.5 (10.5) 16.9 (14.2)*
ICU stay (% yes) 34.0 45.0*
Co-morbidities (%) [ICD-9 code]
nutritional deficiencies [260–269] 28.6 30.5*
peritonitis [567.x, excluding 567.3] 5.4 8.3
cancer [140.x–209.3x] 34.8 40.8*
diabetes mellitus [250.x] 22.9 19.4*
Crohn’s disease [555.x] 1.6 3.2*
Treatment
Duration of PN [d; mean (SD)] 5.2 (4.6) 7.8 (7.8)*
PN volume [mL/d; mean (SD)] 2164 (943) 2145 (1382)
a Medicaid or Medicare.
APR-DRG =All Patient Refined DRG; ICD-9 = International Classification of Diseases, 9th edition; MCB = pre-mixed multi-chamber bag;
PN = parenteral nutrition; *p < 0.01 vs MCB.
2 Using the corrected OR yields a conservative estimate of potentially avoidable BSI. When using a non-
corrected OR, the estimate for potentially avoidable BSI is 2482.
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PN costs by the mean number of PN days for the
total population (equation 5):
Per-patient PN savings ¼ $US91 7:6 days
¼ $US692 ðEq: 5Þ
where $US91 is the adjusted difference in PN cost
per day, and 7.6 is the mean PN days.
Estimated savings per patient due to avoidable
BSI is obtained by multiplying the number of
potentially avoidable BSI by the costs attributable
to BSI, and dividing by the number of patients with
the opportunity to avoid BSI (equation 6):
Avoidable BSI savings¼ ð2172 $US16141Þ
41102
¼ $US853 ðEq: 6Þ
where 2172 is number of potentially avoidable BSI,
$US16141 is the cost attributable to BSI, and
41102 is the number of compounded PN patients.
Total potential per-patient savings were esti-
mated by adding the savings in PN to the savings
due to avoidable BSI (equation 7):
Total per-patient savings¼ $US692þ $US853
¼ $US1545 ðEq: 7Þ
where $US692 is per-patient PN savings, and
$US853 is the avoidable BSI savings.
Figure 2 illustrates total cost savings per pa-
tient, and the results of the sensitivity analysis. The
base case indicates that $US1545 per PN patient
can be saved (PN costs and BSI cost avoidance) if
all PN patients are appropriate candidates to re-
ceive PN viaMCB. If as few as 50% of PN patients
are able to use the standardized formulations
provided inMCBs, savings are reduced to $US773
per PN patient. The extreme sensitivity analysis at
the 95% confidence limits included either the
lowest or the highest values for avoidable BSI,
BSI-attributable costs and adjusted daily PN sav-
ings. The confidence intervals illustrated in figure
2 demonstrate that, even at its most extreme case,
using the 95% lower limit and a 50% appropriate-
ness level, use of MCBs still potentially yields a
$US568 savings per PN patient.
Discussion
The present analysis suggests that there are im-
portant differences in PN costs when compounded
or purchased as a pre-mixed MCB. Savings re-
sulting from lower direct costs (for purchasing
PN components) and cost avoidance (through
potentially fewer BSIs) were considered in this
cost analysis. Results from the sensitivity analysis
indicate that, under even the most extreme sen-
sitivities, use of pre-mixed MCB PN may lead to
significant cost savings.
While the intestinal tract is functional, it is
preferable to utilize the oral or enteral routes to
provide nutrition. EN supports the integrity of



































65% 80% 95% 100%
Fig. 2. Savings per patient by appropriateness for pre-mixed multi-
chamber bag (MCB) parenteral nutrition (PN). Extreme sensitivity
analysis (absolute lower and upper limits) achieved by adding sen-
sitivities of daily PN savings, bloodstream infection (BSI)-attributable
costs and avoidable BSI. Appropriateness for standardized PN via
MCB based on potential needs of each patient population.
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Fig. 1. Bloodstream infection rates in the pre-mixed multi-chamber
bag and compounded parenteral nutrition (PN) groups. Odds ratio
for observed rate = 1.72; 95%CI 1.59, 1.85; p <0.0001. Odds ratio for
adjusted rate =1.56; 95% CI 1.37, 1.79; p <0.0001.
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risk than PN. According to US guidelines, when a
patient is unable to use EN and there is no evi-
dence of protein-calorie malnutrition, PN is not
recommended until after the first 7 days of hos-
pitalization.[34] A key rationale for this relatively
conservative approach to PN therapy centres
around infectious morbidity. Until now, data to
distinguish between the method of PN prepara-
tion and its potential impact on BSI have not
been available, although closed-intravenous sys-
tems (fully collapsible containers that do not use
an external vent to empty the solution, with self-
sealing injection ports), have consistently dem-
onstrated significantly lower incidences of central
venous catheter-associated bacteraemia than
open systems.[35-38] The analysis presented here
may provide a greater understanding of the fac-
tors that influence infection in PN patients.
According to the Healthcare Cost and Utili-
zation Project, there were 220 194 adults in the
US who received PN in 2007.[39,40] When apply-
ing the inclusion and exclusion criteria of this
study (39.3% of patients were excluded for rea-
sons previously articulated), the proportion of
patients receiving PN via MCB (92.7% in the cur-
rent study), and the BSI rates from our analyses
(adjusted rates 16.1% for compounded PN vs 11.3%
for MCB PN), 19947 of the remaining 73048 could
expect to experience a BSI. Of those 19947 BSI,
5947would have been potentially avoidable by using
MCBs (if all PN patients were candidates forMCB).
The number of potentially avoidable BSIs is
reduced when fewer patients are appropriate
candidates for MCB PN: 5650 (with 95% appro-
priate), 4758 (80% appropriate), 3866 (65% ap-
propriate), 2974 (50% appropriate). The large
number of potentially avoidable BSI in the US
each year, with attributable costs of $US16 141
per BSI, could potentially save the US healthcare
system from $US48million (with 50% of patients
appropriate candidates for MCB PN) to $US96
million (100% appropriate) each year. Significantly
greater savings could be realized if the higher BSI
rates found among patients with cirrhosis or renal
failure[30,31] were included in these estimates.
One of the most influential factors in cost is
LOS, and, unsurprisingly, BSI resulted in substan-
tially increased LOS. Further studies have shown
that, after controlling for severity of illness,
patients who received early and sufficient nutri-
tion had significantly shorter LOS,[41-43] with
malnourished patients in one study experiencing
increased LOS of 3.3 days (7.7 – 7 days vs 11 – 9
days; p < 0.0001).[44] Thus, both early clinical nu-
trition and prevention of BSI are important fac-
tors in limiting LOS and, therefore, costs.[45]
Typical of any retrospective analysis, further
study with adequate controls is necessary before
any definitive direction can be taken. This is a
particularly sensitive issue with regards to the
investment in pharmacy clean-rooms and spe-
cially trained personnel that many hospitals have
either undertaken or chosen to outsource to im-
prove the safety of their parenteral preparations.
Despite these investments, 95.4% of US hospitals
purchase pre-mixed large-volume parenteral prod-
ucts, which may include pre-mixed PN.[17] Use of
standardized PN formulae, when compounded
in-hospital, are attributed to a 55.8% reduction in
wasted PN bags and a 36.9% decrease in cost
(labour, materials and inventory), with PN prep-
aration times cut by 66.1% and acquisition costs
of PN reduced by 54.5%.[46] Nonetheless, the
analysis presented here may provide further ideas
for quality improvement and other initiatives to
hospitals.
One of the greatest strengths of conducting
claims database research is the ability to examine
the real-world use of PN on a large scale. How-
ever, this retrospective observational study de-
sign does introduce some limitations. For one,
the inability to randomize exposure limits our
capacity to determine a causal relationship be-
tween PN type and infection rates. Analyses of
these data[30] using a matched propensity score
model created balanced groups of patients receiv-
ing MCB and compounded PN (including mea-
sures of severity). Significant differences in adjusted
BSI rates were found between the groups (MCB
PN 18.8%; compounded PN 24.5%; OR 1.49;
p < 0.001). While these data do not enhance our
ability to identify causality, they do provide ad-
ditional validity to our analysis.
Second, the potential confounders that we
could explore could only include variables mea-
sured in the database and, therefore, we cannot
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guarantee that we have completely accounted for
all sources of variance. Most notably, data on the
type and duration of central access device use
were not reliably available. As such, we could not
calculate intravenous catheter days and were un-
able to report BSI per catheter day as commonly
used by organizations such as the US Centers for
Disease Control and Prevention and the Joint
Commission.[10,24] The medical literature has re-
ported BSI rates with PN in the range of 7.2–39%,
providing an appropriate context for our find-
ings.[13,47] Although central catheters are an in-
fection risk, we were able to include many of the
variables in our analysis that are correlated with
central line use (e.g. diagnosis, co-morbidities,
surgical status, number of hospital PN days).
Finally, although our sensitivity analysis con-
firmed that ICD-9 codes were likely adequate in
identifying BSI, we did not conduct a review of in-
dividual patient records in order to validate these
findings. Nonetheless, the large population in our
analysis provides us with the unique opportunity to
explore these associations with adequate power and
guide further study into this relationship.
Despite the limitations imposed by retro-
spective database analyses, these types of studies
are used by the US FDA to detect and explore
safety signals for marketed drugs.[48] One of the
best-known examples was the identification of
increased coronary symptoms associated with
cyclo-oxygenase (COX)-2 selective NSAIDs in
the early 2000s. Epidemiological studies of large
retrospective databases led to further study, and
eventually the withdrawal of valdecoxib (Bextra)
and refocoxib (Vioxx) from the US market.[48,49]
Conclusions
This analysis represents real-world PN use in
the largest adult hospitalized patient population
to date. The group receiving compounded PN
had more severe illness, a higher observed BSI
rate and a longer LOS than the group that received
MCB PN. Once illness severity and other baseline
variables were accounted for, the adjusted prob-
ability of BSI remained significantly lower for the
MCB than the compounded PN group. The sav-
ings associated with lower PN costs and BSI cost
avoidance may provide an opportunity to re-
duce healthcare spending when PN is delivered via
MCB.
The retrospective nature of these data limits us
to identifying potential associations, and not
causality, between type of PN preparation and
BSI. Nonetheless, these findings may contribute
to an open discussion in the nutrition community
regarding potential risks associated with various
PN products. The analysis presented here dem-
onstrates a clear need for randomized trials to
further explore this critical issue.
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